Replimune Group, Inc.
REPL Nasdaq Biological Products, (No Diagnostic Substances) 金融 FY2017–FY2026
最新收盘价 · 2026年10月23日
$11.46
4.4%Replimune Group, Inc. 的业务
暂无业务介绍。
- 法定名称
- Replimune Group, Inc.
- 财年结束日
- 2026年3月31日
- 最新年报
- 10-K · 2026年6月29日
- 登记号 · CIK
- 0001628280-26-045886
0001737953
营收与利润率
Replimune Group, Inc. 在 2026 财年 营收为 —。
净利润与每股收益
亏损期间以红色显示。
资本回报率
税后营业利润占投入业务资金(债务加股东权益减现金)的比例。
现金流
2026 财年 的自由现金流为 −$285M,占营收的 —。 经营现金流减资本支出。
股息、回购与股数
Replimune Group, Inc. 在 2026 财年 向股东返还 —。 稀释股数增加 15.2%。
资产负债表
现金、债务以及显示 Replimune Group, Inc. 承担债务能力的指标。
| 财年末 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| 现金及短期投资 | $396M | $583M | $421M | $484M | $269M |
| 债务(含融资租赁) | $27.0M | $55.3M | $70.9M | $71.9M | $108M |
| 债务 / 股东权益 | 0.0x | 0.1x | 0.1x | 0.1x | 0.5x |
| 利息保障倍数 | — | −90.2x | −52.2x | −45.3x | −47.1x |
| 流动比率 | 19.5x | 17.5x | 10.7x | 8.0x | 4.8x |
| 速动比率 | 19.5x | 17.5x | 10.7x | 8.0x | 4.8x |
| 总资产 | $461M | $647M | $488M | $551M | $332M |
| 总负债 | $50.0M | $91.3M | $113M | $135M | $166M |
| 股东权益 | $411M | $555M | $375M | $416M | $166M |
| 净债务 (− = 净现金) | −$369M | −$528M | −$350M | −$412M | −$161M |
内部人交易
高管、董事和持股超过 10% 的股东在公开市场的买卖,数据来自 Form 4 申报。“计划”表示依据事先制定的 Rule 10b5-1 计划进行的交易。
买入(12 个月)
$0.0M
0 名内部人士
卖出(12 个月)
$0.0M
0 名内部人士
卖出中按计划执行的比例
—
$0.0M
过去 12 个月没有公开市场的内部人交易。
Piotroski F 分数
关于盈利能力、融资和效率的九项通过/未通过测试。8–9 为强,0–2 为弱。
| 测试项 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| 净利润为正 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 经营现金流为正 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 资产回报率上升 | — | — | ✓ | ✕ | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 经营现金流高于净利润 | ✓ | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| 债务相对资产下降 | — | — | — | — | — | — | ✕ | ✕ | ✓ | ✕ |
| 流动比率上升 | — | — | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 股数未增加 | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 毛利率上升 | — | — | — | — | — | — | — | — | — | — |
| 营收相对资产上升 | — | — | — | — | — | — | — | — | — | — |
| F 分数 | — / 3 | — / 4 | — / 6 | — / 6 | — / 6 | — / 6 | 1 / 7 | 1 / 7 | 2 / 7 | 1 / 7 |
| 应计比率 | — | −5.7% | −5.0% | 4.1% | −5.0% | −7.1% | −8.3% | −5.3% | −10.6% | −7.6% |
| Altman Z'' | — | −1.73 | 11.75 | 5.20 | 15.32 | 10.17 | 7.77 | 0.84 | −0.42 | −13.44 |
10 年数据
金额单位为 USD。将鼠标悬停在指标名称上可查看定义。
| 财年 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| 利润表 | ||||||||||
| 研发支出 | $6.9M | $13.5M | $22.2M | $38.8M | $56.8M | $79.5M | $127M | $175M | $189M | $221M |
| 营业利润 | −$9.6M | −$19.2M | −$30.9M | −$56.2M | −$80.0M | −$118M | −$177M | −$235M | −$262M | −$320M |
| 利息支出 | — | — | — | $0.7M | $0.8M | $0.0M | $2.0M | $4.5M | $5.8M | $6.8M |
| 税前利润 | −$7.7M | −$19.7M | −$30.8M | −$52.6M | −$80.9M | −$118M | −$174M | −$215M | −$247M | −$314M |
| 所得税 | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.3M | $0.4M | $0.5M | −$0.6M |
| 净利润 | −$7.7M | −$19.7M | −$30.8M | −$52.6M | −$80.9M | −$118M | −$174M | −$216M | −$247M | −$314M |
| 归属普通股股东的净利润 | −$7.7M | −$19.7M | −$30.8M | −$52.6M | −$80.9M | −$118M | −$174M | −$216M | −$247M | −$314M |
| 稀释每股收益 | −$1.55 | −$3.96 | −$1.33 | −$1.54 | −$1.75 | −$2.26 | −$2.99 | −$3.24 | −$3.07 | −$3.38 |
| 稀释股数 | 0.00B | 0.00B | 0.02B | 0.03B | 0.05B | 0.05B | 0.06B | 0.07B | 0.08B | 0.09B |
| 现金流 | ||||||||||
| 经营现金流 | −$7.1M | −$16.0M | −$25.4M | −$60.6M | −$61.4M | −$82.2M | −$128M | −$185M | −$192M | −$280M |
| 资本支出 | $0.2M | $0.1M | $2.6M | $6.5M | $2.4M | $2.3M | $2.3M | $5.7M | $6.7M | $4.2M |
| 自由现金流 | −$7.3M | −$16.2M | −$28.0M | −$67.1M | −$63.8M | −$84.5M | −$130M | −$191M | −$199M | −$285M |
| 折旧与摊销 | $0.1M | $0.1M | $0.1M | $0.5M | $1.7M | $2.1M | $2.4M | $2.7M | $3.5M | $3.3M |
| 股权激励 | $0.2M | $0.8M | $2.7M | $7.7M | $11.8M | $24.3M | $28.1M | $34.1M | $35.0M | $32.3M |
| 资产负债表 | ||||||||||
| 现金及短期投资 | $20.7M | $61.6M | $135M | $169M | $476M | $396M | $583M | $421M | $484M | $269M |
| 总债务 | — | — | — | $9.8M | — | $0.0M | $28.6M | $44.8M | $46.4M | $83.3M |
| 融资租赁负债 | — | — | — | $27.4M | $27.2M | $27.0M | $26.6M | $26.1M | $25.5M | $24.8M |
| 流动资产 | — | $64.7M | $141M | $174M | $484M | $404M | $593M | $434M | $496M | $279M |
| 流动负债 | — | $5.2M | $9.9M | $11.9M | $14.5M | $20.8M | $33.8M | $40.4M | $62.4M | $58.2M |
| 固定资产净额 | — | $0.4M | $12.2M | $6.9M | $7.4M | $7.9M | $7.5M | $10.5M | $13.7M | $13.0M |
| 总资产 | — | $65.2M | $154M | $234M | $543M | $461M | $647M | $488M | $551M | $332M |
| 总负债 | — | $6.9M | $16.5M | $50.4M | $44.4M | $50.0M | $91.3M | $113M | $135M | $166M |
| 股东权益 | −$11.5M | −$28.1M | $138M | $184M | $499M | $411M | $555M | $375M | $416M | $166M |
| 回报率 | ||||||||||
| 资本回报率 | — | — | — | −177.8% | — | −600.2% | −25,251.5% | — | — | — |
| 已动用资本回报率 | — | −32.1% | −21.4% | −25.3% | −15.1% | −26.9% | −28.9% | −52.5% | −53.5% | −116.7% |
| 股本回报率 | — | — | −56.2% | −32.7% | −23.7% | −25.9% | −36.1% | −46.4% | −62.6% | −107.9% |
| 资产回报率 | — | −30.2% | −28.1% | −27.1% | −20.8% | −23.5% | −31.5% | −38.0% | −47.6% | −71.1% |
| 有形股本回报率 | — | — | −22.4% | −28.6% | −16.2% | −28.7% | −31.4% | −57.6% | −59.5% | −188.9% |
| 增长 | ||||||||||
| 股数变化 | — | 0.1% | 366.0% | 47.7% | 35.0% | 12.9% | 11.5% | 14.4% | 21.0% | 15.2% |
| 财务健康 | ||||||||||
| 债务 / 股东权益 | — | — | — | 0.1x | — | 0.0x | 0.1x | 0.1x | 0.1x | 0.5x |
| 利息保障倍数 | — | — | — | −76.6x | −97.7x | — | −90.2x | −52.2x | −45.3x | −47.1x |
| 流动比率 | — | 12.5x | 14.3x | 14.7x | 33.3x | 19.5x | 17.5x | 10.7x | 8.0x | 4.8x |
| 速动比率 | — | 12.5x | 14.3x | 14.7x | 33.3x | 19.5x | 17.5x | 10.7x | 8.0x | 4.8x |
| 质量评分 | ||||||||||
| Piotroski F 分数 | — | — | — | — | — | — | 1.0 | 1.0 | 2.0 | 1.0 |
| Altman Z'' | — | −1.7 | 11.8 | 5.2 | 15.3 | 10.2 | 7.8 | 0.8 | −0.4 | −13.4 |
| 应计比率 | — | −5.7% | −5.0% | 4.1% | −5.0% | −7.1% | −8.3% | −5.3% | −10.6% | −7.6% |
来源:SEC EDGAR XBRL 文件 (CIK 0001737953). 数据更新于 2026年10月24日。 第四季度数据为全年减去前九个月。 仅供参考,不构成投资建议。依赖任何数字前,请核对原始文件。
